Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

There Is No Way Buying SNAP Would Help GOOG Stock

By Chris Lau, InvestorPlace Contributor

GOOG stock would get in serious trouble if it were to buy Snap on the dip. The company is better off sticking to its strength in search.

How to Approach Square Stock After Its Downturn

By Chris Lau, InvestorPlace Contributor

The valuation of Square stock is high and investors want SQ to prove its growth is sustainable. Investors should be cautious about SQ stock.

ARWR Stock Sinks After Signing a Big Collaboration Deal

By Chris Lau, InvestorPlace Contributor

ARWR stock fell big after signing a great collaboration agreement with a JNJ unit. The markets are overreacting.

Tilray Could Fall to $50 and Still Be Overvalued

By Chris Lau, InvestorPlace Contributor

Ever since its massive one-day ralley, Tilray stock has been looking to justify its lofty valuation. It's failing.

Achieve Life Sciences Stock Will Probably Tumble Further

By Chris Lau, InvestorPlace Contributor

Achieve Life Sciences stock rallied last week. But ACHV stock price tumbled this week, and ACHV stock is very risky.

Load More